Business / Finance

RSS

inVentiv Health announces completion of PharmaNet acquisition

inVentiv Health, offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced it has completed the acquisition of PharmaNet Development Group, Inc., a recognized leader of global drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries.

14 Jul 2011

Verastem raises $32 million to develop targeted cancer stem cell therapies

Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced today that it has raised $32 million through a Series B financing. Proceeds from the financing will support ongoing research and development and will progress drug candidates into clinical development. The first candidate is projected to enter the clinic in 2012.

14 Jul 2011

DVS Sciences completes $14.6M series A financing

The Ontario Institute for Cancer Research (OICR) and DVS Sciences Inc., today announced that DVS Sciences has completed a $14.6 million series A financing.

14 Jul 2011

Vitrolife second quarter sales increase 19% to SEK 88 million

Vitrolife: Second quarter in brief. Sales growth increased by 31 percent in local currency in the second quarter. Sales amounted to SEK 88 (73) million, corresponding to an increase by 19 percent in SEK.

14 Jul 2011

Humira's early-line growth threatens Enbrel's future uptake in psoriatic arthritis

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that while Amgen/Pfizer's Enbrel was the most widely used tumor necrosis factor (TNF)-alpha inhibitor for recently treated psoriatic arthritis patients in the fourth quarter of 2010, Abbott's Humira has superseded Enbrel as an early-line TNF-alpha inhibitor for newly diagnosed psoriatic arthritis patients. Humira's early-line growth threatens Enbrel's future uptake in psoriatic arthritis.

14 Jul 2011

Orexo acquires Wagner Analysen Technik

Orexo AB has, through its subsidiary Kibion AB, acquired the German company Wagner Analysen Technik GmbH.

14 Jul 2011

Teva acquires Taiyo

Teva Pharmaceutical Industries Ltd. announced today that it has completed the acquisition of effectively 100% of the outstanding shares of Taiyo Pharmaceutical Industry Co. Ltd. for $934 million in cash.

14 Jul 2011

Apax Partners, CPPIB and PSP Investments to acquire KCI for $68.50 per share

Kinetic Concepts, Inc. today announced that it has entered into a definitive merger agreement under which a consortium comprised of funds advised by Apax Partners, together with controlled affiliates of Canada Pension Plan Investment Board and the Public Sector Pension Investment Board, will acquire KCI for $68.50 per share in cash in a transaction valued at $6.3 billion.

13 Jul 2011

Global Health Partner acquires OPA

Global Health Partner has acquired OPA, Ortopædisk Privathospital Aarhus A/S in Århus, Denmark, a specialist clinic operating in the fields of orthopaedics and spine surgery.

13 Jul 2011

Gerresheimer second quarter revenues increase 5.9% to EUR 284.5m

Gerresheimer AG, one of the leading global suppliers to the pharma and healthcare industry, has closed successfully the second quarter of the 2011 financial year

13 Jul 2011

Karo Bio reports net loss of MSEK 124.9 for January - June, 2011

Karo Bio: The January - June period and the second quarter of 2011 in brief. Net loss was MSEK 124.9, whereof the second quarter MSEK 77.2.

13 Jul 2011

Biomet net sales increase 1% to $2.732 billion for fiscal year 2011

Biomet, Inc. announced today preliminary financial results for its fourth quarter and fiscal year ended May 31, 2011.

12 Jul 2011

Novis opens fifth office location in San Luis Obispo

Novis Pharmaceuticals, a leading distributor of critical care products, has officially opened their fifth office location in San Luis Obispo, California. With more than 30 years of industry experience, Novis' aggressive plan to expand their national presence continues to move forward with news of this location opening. Placed strategically between San Francisco and Los Angeles, Novis believes this will help capture parts of the regional market.

11 Jul 2011

Opponents ask Colo. Attorney General to intervene on hospital sale

Opponents mount a challenge to the planned sale of Denver's largest hospital group to a for-profit chain while hospitals in Massachusetts report difficult economic conditions and a California facility is expanding.

11 Jul 2011

American Red Cross acquires HemaCare's red blood cell collection operation assets

HemaCare Corporation announced today that it has reached a definitive agreement to sell certain assets of its Blood Services operations to the American Red Cross. Under the terms of the sale, which closed today, HemaCare sold its red blood cell collection operation assets to the American Red Cross. The sale does not include HemaCare's platelet collection business.

11 Jul 2011

Avisena receives $2.5 million debt facility from Square 1 Bank

Avisena, one of the nation's leading providers of revenue cycle management software and services for physician practices, today announced the extension of a $2.5 million debt facility from Square 1 Bank. The facility will be used to accelerate the Company's strategic expansion into new markets through additional investments in sales and marketing.

11 Jul 2011

Evolution Benefits and Lighthouse1 merge to create Evolution1

Evolution Benefits and Lighthouse1 announced today that they have completed merging their companies to create Evolution1. Evolution1 offers the nation's most comprehensive electronic payment, on-premise and cloud computing solutions for the administration of flexible spending accounts (FSAs), health savings accounts (HSAs), health reimbursement accounts (HRAs), VEBAs, wellness and transit plans.

11 Jul 2011

Anavex exercises warrants to raise $1.575 million

Anavex Life Sciences Corp. is pleased to announce that it has raised $1,575,000 through the exercise of warrants. Funds will be used to continue the Phase I clinical trial of ANAVEX 2-73, the company's lead drug candidate for Alzheimer's disease, to advance other compounds in the Anavex pipeline, and for general corporate purposes.

11 Jul 2011

Generex announces convertible preferred stock securities purchase agreement

Generex Biotechnology Corporation today announced that it entered into a securities purchase agreement with certain institutional investors on July 8, 2011.

11 Jul 2011

Sanofi announces strategic divestiture of dermatology business to Valeant

Sanofi announced today the strategic divestiture of its dermatology business, Dermik, to Valeant Pharmaceuticals International Inc., for a total cash consideration of US $425 million. Valeant is a pharmaceutical company focused on the neurology and dermatology therapeutic areas, based in Mississauga, Ontario, Canada.

11 Jul 2011